PLEKHA4 and invasive breast carcinoma: On the contrary, PLEKHA4 was lower expressed in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical and endocervical cancer (CESC), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and Uterine Corpus Endometrial Carcinoma (UCEC).